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Abstract
Myelodysplastic syndrome (MDS) and aplastic anemia (AA) patients both present with symptoms of bone marrow failure. In
many AA patients, these features are thought to result from an oligoclonal expansion of cytotoxic T-cells that destroy
haematopoietic stem or progenitor cells. This notion is supported by the observation that AA patients respond to
immunosuppressive therapy. A fraction of MDS patients also respond well to immunosuppressive therapy suggesting a
similar role for cytotoxic T-cells in the etiology of MDS, however the role of cytotoxic T-cells in MDS remains unclear. Mice
that express a NUP98-HOXD13 (NHD13) transgene develop a MDS that closely mimics the human condition in terms of
dysplasia, ineffective hematopoiesis, and transformation to acute myeloid leukemia (AML). We followed a cohort of NHD13
mice lacking the Rag1 protein (NHD13/Rag1KO) to determine if the absence of lymphocytes might 1) delay the onset and/or
diminish the severity of the MDS, or 2) effect malignant transformation and survival of the NHD13 mice. No difference was
seen in the onset or severity of MDS between the NHD13 and NHD13/Rag1KO mice. However, NHD13/Rag1KO mice had
decreased survival and showed a trend toward increased incidence of transformation to AML compared to the NHD13 mice,
suggesting protection from AML transformation by a modest immuno-surveillance effect. In the absence of functional Tcrb
signaling in the NHD13/Rag1KO T-cell tumors, Pak7 was identified as a potential Tcrb surrogate survival signal.
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Introduction
Myelodysplastic syndrome (MDS) comprises a heterogeneous
group of clonal stem cell disorders characterized by ineffective
hematopoiesis, peripheral blood cytopenias despite a hypercel-
lular or normocellular bone marrow, and morphologic evidence
of dysplasia. MDS has been associated with a number of genetic
abnormalities, most commonly unbalanced chromosomal aber-
rations such as 5q-, -7/7q-, trisomy 8 and 20q- [1,2] (reviewed
in [3,4]). Mutations in a large number of genes are also
associated with MDS and include ASXL1, DNMT3A, EZH2,
IDH1/IDH2, NRAS/KRAS, RUNX1, TET2 and TP53 (reviewed
in [3,5]). More recently, multiple mutations have been found in
genes integral to the spliceosome complex [6,7,8]. Although less
common, balanced chromosome translocations are also associ-
ated with MDS, eg., t(1;3), t(2;11), t(10;12) and t(11;16)
(November 2011[9]).
Similar to MDS, aplastic anemia (AA) is also characterized by
peripheral blood cytopenias. However, AA is associated with a
hypocellular bone marrow and is thought to be caused in the
majority of cases by an oligoclonal expansion of cytotoxic T-cells
that target and destroy hematopoietic stem and progenitor cells,
resulting in a lack of mature, functional hematopoietic cells [10].
Auto-immune mediated destruction of hematopoietic stem and
progenitor cells has also been proposed to play a role in some cases
of MDS, (reviewed in [4]), and this assertion is supported by the
observation that a subset of MDS patients respond to immuno-
suppressive therapy (reviewed in [11,12]). Additional evidence for
an autoimmune role in a subset of MDS patients includes the
expansion of clonal cytotoxic TCR-Vb T-cell populations which
are depleted after immunosuppressive therapy [13,14,15,16,17],
the preferential response of patients with specific human leukocyte
antigen (HLA) subtypes, and increased levels of selected pro-
inflammatory cytokines (TNFa, IFNc) in the bone marrow
(reviewed in [11,12]).
The fusion gene NUP98-HOXD13 results from the translocation
t(2;11)(q31;p15) and has been detected, albeit only rarely, in MDS
as well as AML patients [18]. Although this translocation is rare in
patients with MDS, it leads to overexpression of HOXA cluster
genes, especially HOXA7 and HOXA9, which is a common finding
in patients with MDS [19,20]. Transgenic mice that express a
NUP98-HOXD13 (NHD13) fusion gene have previously been
shown to develop a MDS that closely resembles human MDS,
with ineffective hematopoiesis, peripheral blood cytopenia, mor-
phologic dysplasia, increased apoptosis, and transformation to
acute leukemia between 8 and 14 months of age [21]. Rag1
deficient mice lack mature T- and B-lymphocytes, due to their
inability to recombine immunoglobulin and T cell receptor genes
[22]. Therefore, to test the hypothesis that a lack of cytotoxic T-
lymphocytes will provide a protective effect against the onset and/
or severity of the MDS that develops in the NHD13 mice, we
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background.
Materials and Methods
Ethics Statement
Animal experiments were approved by the National Cancer
Institute Animal Care and Use Committee.
Transgenic Mice
C57BL/6 NHD13 [21] mice were bred with B6;129S7-
Rag1
tm1Mom/J (Rag1
2/2) mice [22] (Jackson Laboratories, Maine,
USA). The mating strategy involved crossing the C57BL/6
NHD13
+/2 to B6;129S7-Rag1
tm1Mom/J mice to produce
NHD13
+/2Rag1
+/2 and NHD13
2/2Rag1
+/2 progeny. NHD13
+/2
Rag1
+/2 mice were then backcrossed to the B6;129S7-Rag1
tm1Mom/J
mice to generate the study cohorts NHD13
+/2Rag1
+/2, NHD13
+/2
Rag1
2/2, NHD13
2/2Rag1
+/2,a n dNHD13
2/2Rag1
2/2.M i c ew e r e
housed in a Specific Pathogen-Free (SPF) environment. Genomic
DNA isolated from tail biopsies were used to genotype mice using
polymerase chain reaction (PCR) primers as previously described [21]
(for NHD13) or recommended by Jackson Labs (Rag1).
Evaluation of Mouse Health
Mouse health was monitored by serial complete blood counts
(CBCs) and observation. Tail vein peripheral blood was
collected in EDTA-tubes and CBCs were determined every
two months using a HEMAVET Multispecies Hematology
Analyzer (CDC Technologies). Each cohort was followed to
determine course of MDS, potential transformation to leukemia
and cause of death. Mice were euthanized for necropsy and
analysis if CBCs indicated leukemic transformation or severe
anemia (Hemoglobin ,6 grams/dL). Mice were also euthanized
if they displayed non-specific signs of illness such as weight loss,
lethargy, kyphosis, dyspnea, or were moribund. Upon necropsy,
the presence or absence of splenomegaly, hepatomegaly or
enlarged thymus in the leukemic mice was noted. Diagnoses
were determined using a combination of CBCs, necropsy
findings, morphology, histology, immunohistochemistry, and
flow cytometric analysis of bone marrow, spleen, and thymus
if appropriate. Mice were classified according to the Bethesda
proposals for non-lymphoid and lymphoid neoplasms in mice
[23,24].
Flow Cytometry
Single cell suspensions in Hank’s balanced salt solution (HBSS,
Invitrogen) with 2% fetal bovine serum (HF2) were stained with
fluorophore-conjugated antibodies (eBiosciences or BD Pharmin-
gen) and incubated on ice for 45 mins. Following staining, cells
were washed with PBS and re-suspended in HF2 containing
propidium iodide [1 mg/ml] (Sigma), and analysed with a five laser
FACScan (Becton Dickinson).
Immunohistochemistry (IHC)
Tissue sections and hematoxylin-eosin (H&E), myeloperoxi-
dase (DAKO), CD3 (AbD Serotec) and B220/CD45R (Phar-
Mingen) staining, were performed by the Pathology/Histotech-
nology Laboratory (NCI-Frederick) using conventional staining
techniques, on tissue fixed in 10% NBF. Air dried peripheral
blood smears and cytospins of single cell suspensions were
stained with May-Gru ¨nwald-Giemsa for morphological evalua-
tion.
Southern Blot Analyses
Genomic DNA (10 mg) was digested with both HindIII and SstI
independently, separated on a 0.8% agarose gel and transferred to
nylon membranes (Genescreen Plus Hybridisation Transfer
Membrane, Perkin Elmer, Boston MA). Membranes were
hybridised with a
32P labelled TCRB probe (Ready-To-Go DNA
Labelling Beads (-dCTP), Amersham GE Healthcare, UK) to
detect Tcrb1 and Tcrb2 constant regions. Results were detected
using BioMax XAR film (Kodak).
RQ-PCR Mouse Apoptosis Gene Expression Arrays
RNA was isolated from wild type control thymus, NHD13 and
NHD13/Rag1KO thymic tumours using a standard Trizol/
chloroform protocol (Invitrogen). Reverse transcriptase quantita-
tive PCR (RQ-PCR) was used to assay selected genes involved in
apoptosis using a kit from SABiosciences. Briefly, cDNA was
synthesised using the RT
2 First Strand Kit (C-03), and RT
2
Profiler
TM PCR Array Mouse Apoptosis plates (PAMM-012) were
set up with RT
2 SYBR Green/ROX qPCR Master Mix (PA-012).
Data analysis was performed using SABiosciences RT
2 Profiler
PCR Array Data Analysis software (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php).
Statistical Analyses
Graphed data are represented as the mean 6 SEM where
applicable. Statistical significance is calculated using students T-
Test. Mantel-Cox tests were used to determine statistical
significance between survival cohorts, and Two-way Anova for
the MDS and leukemia frequencies in NHD13 vs NHD13/
Rag1KO cohorts.
Results
Lymphocyte Depletion does not Protect NHD13 Mice
from Developing MDS
To test the hypothesis that a lack of mature lymphocytes,
including cytotoxic T cells, would protect NHD13 transgenic mice
from developing MDS, we crossed the NHD13 transgene onto a
Rag1
2/2 background. Given that one copy of the Rag1 gene is
sufficient to produce normal levels of lymphocytes [22], Rag1
+/2
mice were regarded as wild-type (WT) with respect to Rag1. Serial
CBCs were obtained every other month to determine if the mice
had developed evidence of MDS such as pancytopenia or
dysplasia. NHD13
2/2/Rag1
+/2 (hereafter WT) and NHD13
2/2/
Rag1
2/2 (hereafter Rag1KO) had hemoglobin levels that were
indistinguishable from one another, and 3–4 g/dl greater than
NHD13
+/2/Rag1
+/2 (hereafter NHD13) and NHD13
+/2/Rag1
2/2
(hereafter NHD13/Rag1KO) (Figure 1A, Table 1, *[NHD13 vs
WT and NHD13/Rag1KO vs WT] {[NDH13/Rag1KO only vs
WT] indicates timepoints with p=,0.05, t-test). The mean
corpuscular volume (MCV) of the NHD13 and NHD13/Rag1KO
were consistently elevated compared to WT mice, but not different
from one another (Figure 1B). Taken together, these findings
indicate that the Rag1 status does not affect the macrocytic anemia
which develops in the NHD13 mice [21,25].
As expected, the absolute neutrophil count (ANC) was normal
and the absolute lymphocyte count (ALC) was decreased in the
Rag1KO compared to WT, with an ALC of ,1000/uL, compared
to WT controls of ,5000/uL (Figure 1C,D). However, an ALC of
even 1000/uL in Rag1KO mice is somewhat surprising, since these
mice should have no B or T cells. To verify that the Rag1KO
deficiency was not ‘‘leaky’’, we assayed peripheral blood mono-
nuclear cells (PBMCs) for the presence of B220 (a marker of
mature B cells) and CD3 (a marker of mature T cells) (Figure 1E).
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Rag1KO mice or NHD13/Rag1KO mice, indicating that the
knockout was not ‘‘leaky’’ with respect to T and B lymphocytes,
and that the lymphocytes detected by the Coulter counter were
likely to be NK cells or small monocytes. As previously described
[26,27], the NHD13 mice had decreased ANCs and ALCs
(Figure 1C,D, {p=,0.05, t-test), compared to WT. The
NHD13/Rag1KO showed similar differences compared to WT
(Figure 1C,D, {p=,0.05, t-test), however there was no improve-
ment in ANC levels and further reduced ALCs compared to the
NHD13 mice. Both the NHD13 and the NHD13/Rag1KO mice
had an unusual Mac-1
+/B220
+ population (Figure 1E, bottom
row). This Mac-1
+/B220
+ population has been previously
identified in mice expressing the NUP98-HOXD13[25], NUP98-
PHF23 (SG and PDA, unpublished) and CALM-AF10[28,29]
fusion genes.
In addition to the peripheral blood cell counts, there were no
obvious differences in morphologic signs of bone marrow
dysplasia, such as hypersegmented neutrophils, nuclear bridging,
multinucleate cells and blast counts), between the NHD13/
Rag1KO and NHD13 mice (data not shown). Thus, the absence
of lymphocytes, including cytotoxic T-cells, had no effect on the
onset or severity of MDS in this mouse model, suggesting that
cytotoxic T-cells do not play a role in the etiology of MDS in the
NHD13 mouse model.
NHD13/Rag1KO Mice Show a Reduced Survival and Earlier
Transformation to Acute Leukemia
The NHD13/Rag1KO mice demonstrated reduced survival
compared with the NHD13 mice, and all the NHD13/Rag1KO
mice were dead by 14 months of age (Figure 2A, Mantel-Cox,
P=0.01). Median survival of the NHD13 cohort was 13 months
whereas the NHD13/Rag1KO cohort had a median survival of 11
months. The NHD13 mice were less likely to transform to acute
leukemia than were the NHD13/Rag1KO mice (13/19 vs. 17/20),
and more likely to die with progressive MDS (6/19 vs 3/20)
(Figure 2B), although these differences did not reach statistical
significance (P=0.20, Two-way ANOVA). Death from severe
MDS or leukemia was not associated with any age biases.
Previous studies [21,30] have demonstrated that the NHD13
mice develop a range of leukemias, including erythroleukemia,
AML, T-cell ALL, and B-cell ALL. Somewhat surprisingly, given
that the NHD13/Rag1KO mice cannot generate T or B
lymphocytes due to a lack of VDJ recombination, the frequency
of lymphoid leukemias were similar in both the NHD13/Rag1KO
mice (5/20) and the NHD13 mice (6/19) (Table 2). Three
representative NHD13/Rag1KO leukemia subtypes are shown in
Figure 3; Figure 3A shows an example of AML. The CBC
revealed anemia with a hemoglobin of 3.0 g/dL, an elevated
MCV of 72 fL, an elevated WBC of 46,000/mL, and a low platelet
count of 95,000/mL. The bone marrow was infiltrated with sheets
of myeloblasts, and parenchymal organs, including the spleen and
liver, were infiltrated with leukemic blasts. The cells that invaded
the liver stained for both myeloperoxidase and B220, and FACS
analysis demonstrated that the leukemic cells were predominantly
Mac-1
+/Gr-1
+. Of note, many of these Mac-1
+/Gr-1
+ cells were
also positive for B220; a Mac-1
+/Gr-1
+/B220
+ population has
been observed previously in AML caused by overexpression of the
CALM-AF10 [28,29]or NUP98-HOXD13 [25] fusion genes in
mice, and a similar lymphoid-primed multipotential progenitor
population has recently been reported in a subset of human AML
samples [31]. Interestingly, some of the malignant cells seem to
have lost Mac-1 and Gr-1 expression, and express only a B220
‘‘dim’’ population (Figure 3A); this phenomenon has been noted
previously with AML caused by a CALM-AF10 fusion. In that
setting, the B220 dim cells were enriched for leukemia stem cells
[28].
An example of B-ALL (mouse 1841) is shown in Figure 3B. The
CBC from this mouse revealed a hemoglobin of 9.1 g/dL, an
elevated MCV of 60 fL, an elevated WBC of 61.32 K/mL, and a
normal platelet count at 998 K/mL. The bone marrow was
replaced by sheets of lymphoblasts and examination of the liver
showed a perivascular infiltration of B220
+ cells. In contrast to the
AML shown above, these cells were MPO negative. These findings
were consistent with the FACS analysis which demonstrated a
homogeneous B220
+/CD43
+/CD19
2/IgM
- cell population in the
bone marrow (shown), indicative of an immature B-cell pheno-
type, and negative staining for the myeloid antigens Mac-1 and
Gr-1. FACS analysis and IHC of the spleen and cells that had
infiltrated the thymus showed a similar pattern (not shown).
Figure 3C shows findings from a mouse with T-ALL (mouse 1890).
The CBC from this mouse revealed a hemoglobin of 10.6 g/dL,
an elevated MCV of 65 fL, an elevated WBC of 36,500/mL, and a
normal platelet count at 857,000/mL. The normal thymic
architecture was effaced and replaced by sheets of lymphoblasts.
IHC demonstrated cytoplasmic CD3 staining in the thymus, and
the liver showed perivascular invasion of CD3
+ cells. Of note,
despite the fact that IHC was strongly positive for CD3, FACS
analysis demonstrated that the cells were CD3
-CD4
+, and negative
for Mac-1 and Gr-1.
To determine whether the lymphoid cell that is a target for
leukemic transformation is a rare cell that has undergone a
functional Igh or Tcrb gene rearrangement despite the lack of Rag1
protein, as is the case with scid mice that develop pre-T-ALL[32],
we searched for evidence of clonal Igh or Tcrb gene rearrangements
in the B and T cell leukemias, respectively. As shown in figure 3D,
the B- and T-cell malignancies retained the germline configuration
of Igh and Tcrb, respectively. The absence of a clonal Tcrb gene
Figure 1. Peripheral blood (PB) indices are similar in NHD13 and NHD13/Rag1KO mice. Hemoglobin levels (A) are decreased and MCV levels
(B) are increased in NHD13 and NHD13/Rag1KO mice; the decline in MCV at 12 and 14 months is likely due to death of the more severely affected
mice. (C) and (D) Neutrophil and lymphocyte counts; results in C and D exclude mice that have transformed to leukemia (WBC .20 K/mL). Error bars in
A-D represent the standard deviation. Timepoints with p values ,0.05 are indicated as follows; (*) indicates significance for both NHD13 vs WT and
NHD13/Rag1KO vs WT comparisons, ({) NHD13/Rag1KO vs WT only, and ({) NHD13 vs WT only. The number of mice at each time point varies as mice
die over time (Table 1). (E) Representative FACS analysis of PB from mice of each genotype, aged 8 months, stained with the indicated antibodies.
doi:10.1371/journal.pone.0036876.g001
Table 1. Number of mice evaluated by serial CBC.*
Age (months)
Genotype 8 10 12 14
NHD13 17 13 9 4
NHD13/Rag1KO 24 15 7 0
WT 14 14 11 11
Rag1KO 13 13 10 11
*mice transformed to leukemia are not included.
doi:10.1371/journal.pone.0036876.t001
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mouse #1890 were positive for cytoplasmic CD3, but negative for
surface CD3. Tcrb is required for the CD3/TCR complex to form
in the ER and delivery of the CD3/TCR complex to the plasma
membrane [33,34]. Since NHD13/Rag1KO mice do not produce
Tcrb, but can produce CD3, the CD3 protein therefore remains in
the ER.
Pak7 May Replace Tcrb as a T-cell Survival Signal in the
NHD13/Rag1KO Mice
The development of lymphoid leukemias was an unanticipated
finding in the NHD13/Rag1KO mice. During normal thymocyte
differentiation, positive selection via the TCR ensures T-cell
rescue from apoptosis and directs further differentiation to the
CD4/CD8 double positive stage (reviewed in [35,36]). We have
previously demonstrated that scid mice, which are also defective in
VDJ joining, are relatively protected against the oncogenic effects
of SCL and LMO1 transgenes, and that the T-ALLs that do
develop in these mice universally have an in-frame Tcrb gene
rearrangement, suggesting that the rare ‘‘leaky’’ scid thymocyte
with a functional Tcrb is the target for malignant transformation.
However, the Rag1KO is not leaky, and we saw no evidence of
Tcrb gene rearrangements in the T-ALLs that arose in the
NHD13/Rag1KO mice. Therefore, in the absence of T-cell
receptor signaling, it is reasonable to predict that an alternative
survival signal may be functional in the NHD13/Rag1KO T-cell
ALLs.
We sought to identify alternative survival signals in the NHD13/
Rag1KO pre-T-ALL by assessing the expression levels of genes
known to be involved in apoptotic pathways. We used Mouse
Apoptosis RT
2 Profiler PCR Arrays to compare the expression
levels of 84 genes involved in programmed cell death using pre-T-
ALL samples from NHD13/Rag1KO and NHD13 mice, and wild
type thymus controls. We reasoned that the best candidate genes
for an alternative survival signal would be increased in NHD13/
Rag1KO pre-T-ALL compared to WT thymus, and also increased
in NHD13/Rag1KO pre-T-ALL compared to NHD13 pre-T-ALL
(Figure 4a). However, Casp1was the sole gene identified in this
screen, which was a poor candidate as an alternative survival
signal given its role in promoting apoptosis [37]. We next
identified genes that were overexpressed in both the NHD13/
Rag1KO pre-T-ALL as well as the NHD13 pre-T-ALL, reasoning
that the alternative survival signal may be common to the NHD13
background. This second screen identified the anti-apoptotic Pak7
gene (20-fold increased) as the most dramatically overexpressed
gene in the groups compared (Table 3). Bnip3 (5.6-fold increased)
was also overexpressed, but as a pro-apoptotic gene [38,39,40]
appears to be an unlikely candidate for an alternative survival
signal. There were no genes which were downregulated in the
NHD13/Rag1KO pre-T-ALL compared to WT thymus, and also
downregulated in the NHD13/Rag1KO compared to the NHD13
pre-T-ALL. However, 15 downregulated genes were common to
both the NHD13/Rag1KO pre-T-ALL vs WT Thy and NHD13
pre-T-ALL vs WT Thy differential gene expression comparisons
(Figure 4b). The downregulation of the pro-apoptotic genes Dffa,
Fas, Trp53inp1, Trp63, and Tnfrsf1 suggests that these genes might
also promote the survival of the pre-T-ALL cells.
Discussion
Expression of a NUP98-HOXD13 fusion gene in mice, has been
shown to recapitulate the key features of human MDS, including
peripheral blood cytopenias, dysplasia, increased apoptosis,
ineffective hematopoiesis, and transformation to AML
[21,25,26,27]. However, none of these features differed between
NHD13 and NHD13Rag1KO mice, which lack T and B
Figure 2. NHD13/Rag1KO mice have decreased survival and an increased incidence of leukemia. (A) Survival is dramatically reduced in the
NHD13 mice and further decreased in the NHD13/Rag1KO cohort (Mantel Cox test p=0.01); median lifespan of the NHD13/Rag1KO mice is two
months less than the NHD13 cohort. (B) Transformation to leukemia was 25% higher in the NHD13/Rag1KO mice compared with NHD13. Twenty-five
percent and 26% of mice were found dead in the NHD13 and NHD13/Rag1KO cohorts respectively, and were unavailable for necropsy, therefore these
mice were excluded from the analyses in panel B.
doi:10.1371/journal.pone.0036876.g002
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not involved in the form of MDS produced by the NHD13 fusion
gene, and therefore does not reflect the biology of immunosupres-
sion-responsive bone marrow failure that occurs in some MDS
patients.
The NHD13 mice displayed a modest (median 13 months vs 11
months) survival advantage compared to the NHD13/Rag1KO
mice (p=0.01). There was a non-significant trend toward an
increased incidence of death due to leukemic transformation, as
opposed to severe MDS, in the NHD13/Rag1KO compared to the
NHD13 mice. Somewhat surprisingly, there was no obvious
difference in the proportion of lymphoid and myeloid leukemias in
the NHD13/Rag1KO compared to the NHD13 mice. There were
no obvious differences in clinical presentation, gross necropsy
findings, immunohistochemistry, or flow cytometry findings in the
AML that developed in the NHD13/Rag1KO mice compared to
the NHD13 mice. Since Rag1 deficient mice have far fewer
immature T and B cells than do WT mice, we had anticipated that
the NHD13/Rag1KO would have far fewer T or B cell leukemias
compared to the NHD13 mice. However, the B- and T-ALLs that
developed in the NHD13/Rag1KO mice involved immature B-
and T-cell precursors, consistent with previous reports of B-
ALL[41,42] and T-ALL[43] in Rag1KO mice. Similar to the
lymphoid maligancies that arose in the NHD13/Rag1KO mice, the
lymphoid leukemias that arose in the reports cited above all
developed in the context of engineered mutations, such as deletion
of p19Arf, Trp53, or overexpression of Myc.
There was a minor but significant survival disadvantage of the
NHD13/Rag1KO mice compared to the NHD13 mice (Figure 2A).
Although it is possible that this survival disadvantage was due to
infections of the immunodeficient NHD13/Rag1KO mice, we saw
no findings on necropsy that would support this possibility, and
there was no difference in survival of Rag1KO compared to WT
mice (Figure 2A), which were housed in a Specific Pathogen Free
(SPF) environment. It is possible that the improved survival was
due in part to an immuno-surveillance mechanism (reviewed in
[44]) present in the NHD13 mice but lacking in the NHD13/
Rag1KO mice. The absence of T- and B-cells, which normally
mediate cellular immunity, transplant rejection, and elimination of
nascent malignancies through antigen recognition, cytokine
Table 2. Summary of Diagnoses.
No. NHD13 Age/month Diagnosis No. NHD13/Rag1KO Age/month Diagnosis
1 A1839 10 MDS 1 A1838 12 MDS
2 A1855 13.5 MDS 2 A1910 13.5 MDS
3 A1877 14.5 MDS 3 A1929 12 MDS
4 A1888 14 MDS 4 A1854 11 AML
5 A1918 13.5 MDS 5 A1856 12 AML
6 A1962 17 MDS 6 A1860 10 AML
7 A1851 10 AML 7 A1896 14 AML
8 A1895 12 AML 8 A1907 14 AML
9 A1898 14 AML 9 A1914 13 AML
10 A1917 13 AML 10 A1916 8 AML
11 A1921 14 AML 11 A1933 11.5 AML
12 A1971 8 AML 12 A1943 12 AML
13 A1967 18 AML* 13 A1950 10 AML
14 A1848 12 B-ALL 14 A1951 12 AML
15 A1904 12.5 B-ALL 15 A1841 14 B-ALL
16 A1927 11.5 B-ALL 16 A1926 12 B-ALL
17 A1931 12 B-ALL 17 A1966 11.5 B-ALL
18 A1853 11 T-ALL 18 A1890 10 T-ALL
19 A1915 13 T-ALL 19 A1897 10 T-ALL
20 A1837 13.5 FD/unknown 20 A1894 7 Leukemia NOS**
21 A1862 12 FD/unknown 21 A1842 10 FD/unknown
22 A1922 14 FD/unknown 22 A1861 8 FD/unknown
23 A1924 13 FD/unknown 23 A1902 10 FD/unknown
24 A1938 9.5 FD/unknown 24 A1925 10 FD/unknown
25 A1953 9 FD/unknown 25 A1940 9 FD/unknown
26 A1952 9 FD/unknown
27 A1961 8 FD/unknown
*Euthanised at end of study – mouse asymptomatic although CBC at euthanasia showed elevated WBCs (24.78 K/mL) and neutrophils (19.52 K/mL). Splenomegaly
observed upon necropsy. H&E showed perivascular infiltration of the liver with invading cells approximately 50% MPO+ by IHC. FACS showed BM 54% Mac-1
+/Gr-1
+,
40% Ter119
+ and spleen 25% Mac-1
+/Gr-1
+, 75% Ter119
+.
**NOS, not otherwise specified – mouse found dead, with hepatosplenomegaly. H&E showed extensive parenchymal invasion of blasts in the liver, spleen and kidney.
IHC shows invasive cells to be B220-, CD3- and MPO-.
doi:10.1371/journal.pone.0036876.t002
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blasts and immature neutrophils in the bone marrow (left panel). Perivascular infiltration of MPO
+/B220
+ cells is shown in the liver (middle panels)
and a Mac-1
+Gr-1
+B220
+ population dominates both the bone marrow and spleen tissues (FACS plots, right). (B) Representative B-ALL (# 1841). Bone
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to AML. This hypothesis would be supported by the trend toward
increased AML transformation in the NHD13/Rag1KO mice
compared to the NHD13 mice (Figure 2B). However, given that
the survival advantage was only two months, the effect is modest.
Of note, a similar moderate survival advantage was observed in
crosses of Rag1KO mice to other oncogenic backgrounds, such as
those described above[41,42,43]. Interestingly, a RAG1
2/2
genotype also denotes a high-risk group with poorer survival in
human B-ALL, again supporting the hypothesis that immune-
mediated surveillance may be important in the elimination of fully
transformed malignant cells [45,46].
Given that the pre-T-ALL which arose in the NHD13/Rag1KO
mice did not have Tcrb gene rearrangements, Tcrb could not have
provided a survival signal to the malignant T cells. We used
apoptosis focused gene arrays in an attempt to identify alternative
candidates that may have provided a survival signal. Pak7(Pak5)
was found to be upregulated 20-fold in the pre-T-ALL that
developed in the NHD13/Rag1KO mice, and is an attractive
candidate for such a survival signal. PAK7 is normally expressed in
the brain and is a member of the p21-activated kinase (PAK)
family of proteins that act as upstream regulators of the MAPK
signaling pathway[47]. TCR signaling normally activates JNK,
p38 and NF-kB signaling pathways to instigate T-cell survival and
activation (reviewed in [48]). Overexpression of PAK7 activates the
JNK kinase pathway[47] and can protect cells from apopto-
sis[49,50,51] thereby providing a viable survival stimulus in the
absence of TCR. Various members of the PAK kinase family have
been found to be overexpressed in cancers of the esophagus,
breast, colon, liver, kidney, ovary, prostate, bladder, pancreas and
brain, in neurofibromatosis, and in T-cell lymphoma (reviewed
in[52,53]). Taken together, although further studies would be
required to prove that overexpression of Pak7 provides a critical
survival signal for the NHD13/Rag1KO pre-T-ALL, Pak7 is a
candidate for this function.
The findings presented here demonstrate the MDS which
develops in NHD13 mice is not dependent on an intact immune
system, and is therefore not dependent on cytotoxic T-cells.
Surprisingly, the NHD13/Rag1KO mice were not protected
against lymphoid leukemias, and had a decreased survival
compared to the NHD13 only mice. An alternative survival signal
for the pre-T-ALL that developed in the NHD13/Rag1KO may
have been the marked overexpression of Pak7 seen in these mice.
Given that MDS is a heterogeneous disease, it is important to note
that, although cytotoxic T-cells do not play a role in the
development of MDS caused by a NHD13 transgene, these
findings do not preclude an effect of cytotoxic T-cells in MDS
caused by other mechanisms.
marrow replaced with lymphoblasts (left panel). Perivascular infiltration of B220
+ cells in the liver is evident (middle panel), and FACS (right) shows
the abnormal population to be B220
+CD43
+CD19
-SIgM
-CD3
-Mac-1
-Gr-1
-. (C) Representative T-ALL (#1890). Cytospin reveals sheets of lymphoblasts;
inset shows cytoplasmic CD3 staining of thymic blasts. Perivascular infiltration of CD3
+ cells is shown in the liver (lower panel). FACS (right) revealed a
CD3
2/CD4
+ cell population in the thymus. (D) Southern hybridization with IgH (left panel) and TCRb (right panel) probes. Left panel, WT and 1841 BM
shows germline IgH genomic configuration. 1848 B-ALL is a representative Rag1 competent NHD13 mouse with B-ALL, showing clonal IgH gene
rearrangement (black arrow). Right panels show 1890 and 1897 T-ALL genomic DNA with the TCR locus in germline configuration (red arrows). Wild-
type thymus shows expected loss of the CB1 fragment, and wild type bone marrow (WT BM) demonstrates germline TCR configuration. + control,
TCR rearranged positive control DNA from the same Southern blot. M, l HindIII ladder.
doi:10.1371/journal.pone.0036876.g003
Figure 4. Differential expression of apoptosis pathway genes in T-ALLs of NHD13 and NHD13/Rag1KO mice. Venn diagram of genes 4-
fold elevated (A) or decreased (B) in comparison groups (1) NHD13/Rag1KO T-ALL vs NHD13 T-ALL, (2) NHD13 T-ALL vs WT Thy and (3) NHD13/Rag1KO
T-ALL vs WT Thy. Casp1 is common to group (1) and (3), and Pak7 and Bnip3 common to (2) and (3). The genes listed in (B) are common to groups (2)
and (3).
doi:10.1371/journal.pone.0036876.g004
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